5-Hydroxy-4-oxo-L-norvaline
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-01020 |
| CAS | 26911-39-7 |
| Molecular Weight | 147.13 |
| Molecular Formula | C5H9NO4 |
Online Inquiry
Description
5-Hydroxy-4-oxo-L-norvaline is an antifungal antibiotic produced by Streptomyces akiyoshiensis. It can inhibit protein biosynthesis.
Specification
| Related CAS | 4439-84-3 |
| Synonyms | 5-hydroxy-4-oxonorvaline; Antibiotic RI-331 |
| IUPAC Name | (2S)-2-amino-5-hydroxy-4-oxopentanoic acid |
| Canonical SMILES | C(C(C(=O)O)N)C(=O)CO |
| InChI | InChI=1S/C5H9NO4/c6-4(5(9)10)1-3(8)2-7/h4,7H,1-2,6H2,(H,9,10)/t4-/m0/s1 |
| InChI Key | FRTKOPTWTJLHNO-BYPYZUCNSA-N |
Properties
| Antibiotic Activity Spectrum | fungi |
| Boiling Point | 363.8±37.0 °C at 760 mmHg |
| Melting Point | 100°C(dec.) |
| Density | 1.4±0.1 g/cm3 |
Reference Reading
1. Lassa fever or lassa hemorrhagic fever risk to humans from rodent-borne zoonoses
Mamdouh M El-Bahnasawy, Laila Abdel-Mawla Megahed, Hala Ahmed Abdalla Saleh, Tosson A Morsy J Egypt Soc Parasitol. 2015 Apr;45(1):61-70. doi: 10.12816/0010850.
Viral hemorrhagic fevers (VHFs) typically manifest as rapidly progressing acute febrile syndromes with profound hemorrhagic manifestations and very high fatality rates. Lassa fever, an acute hemorrhagic fever characterized by fever, muscle aches, sore throat, nausea, vomiting, diarrhea and chest and abdominal pain. Rodents are important reservoirs of rodent-borne zoonosis worldwide. Transmission rodents to humans occur by aerosol spread, either from the genus Mastomys rodents' excreta (multimammate rat) or through the close contact with infected patients (nosocomial infection). Other rodents of the genera Rattus, Mus, Lemniscomys, and Praomys are incriminated rodents hosts. Now one may ask do the rodents' ectoparasites play a role in Lassa virus zoonotic transmission. This paper summarized the update knowledge on LHV; hopping it might be useful to the clinicians, nursing staff, laboratories' personals as well as those concerned zoonoses from rodents and rodent control.
2. Posterior Reversible Encephalopathy Syndrome
Alexandra N Gewirtz, Virginia Gao, Sarah C Parauda, Matthew S Robbins Curr Pain Headache Rep. 2021 Feb 25;25(3):19. doi: 10.1007/s11916-020-00932-1.
Purpose of review: This review provides an updated discussion on the clinical presentation, diagnosis and radiographic features, mechanisms, associations and epidemiology, treatment, and prognosis of posterior reversible encephalopathy syndrome (PRES). Headache is common in PRES, though headache associated with PRES was not identified as a separate entity in the 2018 International Classification of Headache Disorders. Here, we review the relevant literature and suggest criteria for consideration of its inclusion. Recent findings: COVID-19 has been identified as a potential risk factor for PRES, with a prevalence of 1-4% in patients with SARS-CoV-2 infection undergoing neuroimaging, thus making a discussion of its identification and treatment particularly timely given the ongoing global pandemic at the time of this writing. PRES is a neuro-clinical syndrome with specific imaging findings. The clinical manifestations of PRES include headache, seizures, encephalopathy, visual disturbances, and focal neurologic deficits. Associations with PRES include renal failure, preeclampsia and eclampsia, autoimmune conditions, and immunosuppression. PRES is theorized to be a syndrome of disordered autoregulation and endothelial dysfunction resulting in preferential hyperperfusion of the posterior circulation. Treatment typically focuses on treating the underlying cause and removal of the offending agents.
3. Antifungal dipeptides incorporating an inhibitor of homoserine dehydrogenase
Andrzej S Skwarecki, Marta Schielmann, Dorota Martynow, Marcin Kawczyński, Aleksandra Wiśniewska, Maria J Milewska, Sławomir Milewski J Pept Sci. 2018 Jan;24(1). doi: 10.1002/psc.3060.
The antifungal activity of 5-hydroxy-4-oxo-l-norvaline (HONV), exhibited under conditions mimicking human serum, may be improved upon incorporation of this amino acid into a dipeptide structure. Several HONV-containing dipeptides inhibited growth of human pathogenic yeasts of the Candida genus in the RPMI-1640 medium, with minimal inhibitory concentration values in the 32 to 64 μg mL-1 range. This activity was not affected by multidrug resistance that is caused by overexpression of genes encoding drug efflux proteins. The mechanism of antifungal action of HONV dipeptides involved uptake by the oligopeptide transport system, subsequent intracellular cleavage by cytosolic peptidases, and inhibition of homoserine dehydrogenase by the released HONV. The relative transport rates determined the anticandidal activity of HONV dipeptides.
Recommended Products
| BBF-03754 | CASTANOSPERMINE | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
